Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain.
Alonso Torres AM, Arévalo Bernabé AG, Becerril Ríos N, Hellín Gil MF, Martínez Sesmero JM, Meca Lallana V, Ramió-Torrentà L, Rodríguez-Antigüedad A, Gómez Maldonado L, Triana Junco I, Gómez-Barrera M, Espinoza Cámac N, Oyagüez I. Alonso Torres AM, et al. Among authors: meca lallana v. Pharmacoecon Open. 2023 May;7(3):431-441. doi: 10.1007/s41669-023-00394-2. Epub 2023 Feb 21. Pharmacoecon Open. 2023. PMID: 36802327 Free PMC article.
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
Meca-Lallana JE, Oreja-Guevara C, Muñoz D, Olascoaga J, Pato A, Ramió-Torrentà L, Meca-Lallana V, Hernández MA, Marzo ME, Álvarez-Cermeño JC, Rodríguez-Antigüedad A, Montalbán X, Fernández O; Spanish GILENYA Registry Investigators. Meca-Lallana JE, et al. Among authors: meca lallana v. PLoS One. 2021 Oct 13;16(10):e0258437. doi: 10.1371/journal.pone.0258437. eCollection 2021. PLoS One. 2021. PMID: 34644366 Free PMC article.
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Brieva L, Estruch BC, Merino JAG, Meca-Lallana V, Río J, Rodríguez-Antigüedad A, Agüera E, Ara JR, Luque AA, Garcia CA, Blanco Y, Castillo-Triviño T, Costa-Frossard L, González Platas M, Pascual LL, Llaneza-González M, Ginés MLM, Matías-Guiu J, Meca-Lallana JE, Bilbao MM, Sempere AP, Romero-Pinel L, Saiz A, Moral E. Brieva L, et al. Among authors: meca lallana v, meca lallana je. Mult Scler Relat Disord. 2022 Jul;63:103805. doi: 10.1016/j.msard.2022.103805. Epub 2022 Apr 12. Mult Scler Relat Disord. 2022. PMID: 35512501 Review.
[15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part I)].
Fernández O, Montalban X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Mongay-Ochoa N, Moral E, Oreja-Guevara C, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Rodríguez-Antigüedad A. Fernández O, et al. Among authors: meca lallana v. Rev Neurol. 2023 Jul 1;77(1):19-30. doi: 10.33588/rn.7701.2023167. Rev Neurol. 2023. PMID: 37365721 Free PMC article. Review. Spanish.
[15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part II)].
Fernández O, Montalban X, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Mongay-Ochoa N, Moral E, Oreja-Guevara C, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Rodríguez-Antigüedad A. Fernández O, et al. Among authors: meca lallana v. Rev Neurol. 2023 Jul 16;77(2):47-60. doi: 10.33588/rn.7702.2023168. Rev Neurol. 2023. PMID: 37403243 Free PMC article. Review. Spanish.
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
Meca-Lallana J, Ayuso T, Martínez-Yelamos S, Durán C, Contreras Martín Y, Herrera Navarro N, Pérez Sempere A, Álvarez-Cermeño JC, Millán Pascual J, Meca-Lallana V, Romero Sevilla R, Ricart J. Meca-Lallana J, et al. Among authors: meca lallana v. Eur Neurol. 2020;83(1):25-33. doi: 10.1159/000505778. Epub 2020 Mar 18. Eur Neurol. 2020. PMID: 32187609 Free PMC article.
Cognitive impairment in multiple sclerosis: diagnosis and monitoring.
Meca-Lallana V, Gascón-Giménez F, Ginestal-López RC, Higueras Y, Téllez-Lara N, Carreres-Polo J, Eichau-Madueño S, Romero-Imbroda J, Vidal-Jordana Á, Pérez-Miralles F. Meca-Lallana V, et al. Neurol Sci. 2021 Dec;42(12):5183-5193. doi: 10.1007/s10072-021-05165-7. Epub 2021 Apr 1. Neurol Sci. 2021. PMID: 33796947 Free PMC article. Review.
[Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Mallada-Frechin J, Meca-Lallana V, Barrero F, Martinez-Gines ML, Marzo-Sola ME, Ricart J, Garcia E, En Representacion de Los Investigadores Del Estudio Ms Next ERLIDEMN. Mallada-Frechin J, et al. Among authors: meca lallana v. Rev Neurol. 2018 Sep 1;67(5):157-167. Rev Neurol. 2018. PMID: 30047118 Free article. Spanish.
60 results